Press Releases April 29, 2026 06:00 PM

17 Education & Technology Group Inc. Files Its Annual Report on Form 20-F

17 Education & Technology Group Inc. Files Annual Report on Form 20-F for Fiscal Year 2025

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
YQ

17 Education & Technology Group Inc., a leading Chinese education technology company, announced the filing of its annual report on Form 20-F with the SEC for the fiscal year ended December 31, 2025. The report includes audited financial statements and is accessible via the company's investor relations website and the SEC's website. The company offers smart classroom solutions and SaaS products aimed at enhancing teaching and learning efficiency in Chinese schools.

17 Education & Technology Group Inc. Files Its Annual Report on Form 20-F
YQ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The company filed its 2025 annual report on Form 20-F with audited financials, ensuring regulatory transparency.
  • 17EdTech provides data-driven, personalized education technology solutions primarily for Chinese schools, focusing on SaaS offerings for digital transformation in education.
  • The annual report is freely available to shareholders, ADS holders, and the public, indicating openness in investor communications.

BEIJING, April 29, 2026 (GLOBE NEWSWIRE) -- 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced that it filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission (the “SEC”) on April 29, 2026. The annual report can be accessed on the Company’s investor relations website at https://ir.17zuoye.com as well as on the SEC’s website at http://www.sec.gov.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to ir@17zuoye.com.

About 17 Education & Technology Group Inc.

17 Education & Technology Group Inc. is a leading education technology company in China, offering smart in-school classroom solution that delivers data-driven teaching, learning and assessment products to teachers, students and parents. Leveraging its extensive knowledge and expertise obtained from in-school business over the past decade, the Company provides teaching and learning SaaS offerings to facilitate the digital transformation and upgrade at Chinese schools, with a focus on improving the efficiency and effectiveness of core teaching and learning scenarios such as homework assignments and in-class teaching. The product utilizes the Company’s technology and data insights to provide personalized and targeted learning and exercise content that is aimed at improving students’ learning efficiency.

For investor and media inquiries, please contact:

17 Education & Technology Group Inc.
Ms. Lara Zhao
Investor Relations Manager
E-mail: ir@17zuoye.com


Risks

  • The company's business is predominantly focused on the Chinese education sector, which may be subject to regulatory changes impacting profitability.
  • Market adoption and competition in education technology could affect the company’s growth and financial performance.
  • Dependence on digital transformation in the education system may face uncertainties related to technology trends and government policies.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026